The promise and pitfalls of monoclonal antibody therapeutics

Current Opinion in Biotechnology

Volumn 7, Issue 6, 1996, Pages 622-628

  Berkower, Ira ^a  

^a Food and Admin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; OKT 3; TUMOR ANTIGEN; YTTRIUM 90;

CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC IMAGING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW;

EID: 0030560995     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(96)80073-5     Document Type: Article

References (50)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature. 256:1975;495-497.
2. Goldstein G. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 313:1985;337-342.
3. Berkower I. Toxicity of monoclonal antibodies and conjugates. Newcombe DS, Rose NR, Bloom JC. Clinical Immunotoxicology. 1992;83-91 Raven Press, New York.
4. Hirsch R, Eckhaus M, Auchincloss H Jr, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol. 140:1988;3766-3772.
5. Hirsch R, Archibald J, Gress RE. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab)2 fragments of anti-CD3 monoclonal antibody: F(ab)2 fragments induce a selective T helper dysfunction. J Immunol. 147:1991;2088-2093.
6. Henrickson M, Reid J, Bellet JS, Sawchuk SS, Hirsch R. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha/beta (H57-597) and CD3 (145-2C11). Transplantation. 60:1995;828-835.
7. Waldmann TA. The interleukin-2 receptor. J Biol Chem. 266:1991;2681-2684.
8. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med. 162:1985;358-362.
9. Tighe H, Friend PJ, Collier SJ, Decurtins M, Lim S, Cobbold SP, Thiru S, Calne RY, Waldmann H. Delayed allograft rejection in primates treated with anti-IL-2 receptor monoclonal antibody Campath-6. Transplantation. 45:1988;226-228.
10. Van Gelder T, Zietse R, Mulder AH, Yzermans JN, Hesse CJ, Vaessan LM, Weimar W. A double-blind placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration in the prevention of acute rejection after kidney transplantation. Transplantation. 60:1995;248-252.
11. Van Gelder T, Balk AHMM, Jonkman FAM, Zietse R, Zondervan P, Hess CJ, Vaessen LMB, Mochtar B, Weimar W. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation. 62:1996;51-55.
12. Brown PS Jr, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, Junghans RP, Queen C, Hakimi J, Benjamin WR, et al. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA. 88:1991;2663-2667.
13. Greiner JW, Guadagni F, Roselli M, Nieroda CA. Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine. Anticancer Res. 16:1996;2129-2134.
14. Rodwell JD, Alvarez VL, Lee C, Lopes AD, Goers JWF, King HD, Powsner HJ, McKearn TJ. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci USA. 83:1986;2632-2636.
15. Fritzberg AR, Abrams PG, Beaumier PL, Kasina S, Morgan AC, Rao TN, Reno JM, Sanderson JA, Srinivasan A, Wilbur DS, Vanderheyden J-L. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc Natl Acad Sci USA. 85:1988;4025-4029.
16. Coons T. Monoclonal antibodies: the promise and the reality. of special interest Radiol Technol. 67:1996;39-59 A good review of radiolabeled antibodies for imaging or therapy.
17. Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintigraphy in patients with colorectal, ovarian and prostate cancer. Cancer. 72:1993;3453-3462.
18. Vansant JP, Johnson DH, O'Donnell DM, Stewart JR, Sonin AH, McCook BM, Powers TA, Salk DJ, Frist WH, Sandler MP. Staging lung carcinoma with a Tc-99m labeled monoclonal antibody. Clin Nucl Med. 17:1992;431-438.
19. Collier BD, Abdel-Nabi H, Doerr RJ, Harwood SJ, Olsen J, Kaplan EH, Winzelberg GG, Grossman SJ, Krag DN, Mitchell EP. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology. 185:1992;179-186.
20. Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer: results of a multicenter clinical study. Ann Surg. 214:1991;118-124.
21. Balaban EP, Walker BS, Cox JV, Bordlee RP, Salk D, Abrams PG, Sheehan RG, Frenkel EP. Detection and staging of small cell lung carcinoma with a technetium-labeled monoclonal antibody: a comparison with standard staging methods. Clin Nucl Med. 17:1992;439-445.
22. Breitz HB, Sullivan K, Nelp WB. Imaging lung cancer with radiolabeled antibodies. Semin Nucl Med. 23:1993;127-132.
23. Rusch V, Macapinlac H, Heelan R, Kramer E, Larson S, McCormack P, Burt M, Martini N, Ginsberg R. Nr-Lu-10 monoclonal antibody scanning: a helpful new adjunct to computed tomography in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg. 106:1993;200-204.
24. Roselli M, Guadagni F, Buonomo O, Belardi A, Ferroni P, Diodati A, Anselmi D, Cipriani C, Casciani CU, Greiner J, Schlom J. Tumor markers as targets for selective diagnostic and therapeutic procedures. Anticancer Res. 16:1996;2187-2192.
25. Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science. 252:1991;1657-1662.
26. Thrush GR, Lark LR, Clinchy BC, Vitetta ES. Immunotoxins: an update. Annu Rev Immunol. 14:1996;49-72.
27. Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, Roessler E, Horak ID, Zaknoen S, Kasten-Sportes C, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 82:1993;1701-1712.
28. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, Brechbiel MW, Jaffe ES, Fleisher TA, Goldman CK, et al. Radioimmunotherapy of interleukin-2Ra-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. of special interest Blood. 86:1995;4063-4075 An interesting example of the antireceptor strategy. References [27] and [28] allow comparison between the same monoclonal antibody alone or with radioisotope attached.
29. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. J Am Med Assoc. 266:1991;1097-1102.
30. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 324:1991;429-436.
31. Wortel CH, Von der Mohlen MAM, Van Deventer SJH, Sprung CL, Jastremski M, Lubbers MJ, Smith CR, Allen IE, Ten Cate JW. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in Gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis. 166:1992;1367-1374.
32. Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Eng J Med. 326:1992;1153-1157.
33. Baumgartner J-D. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infect Dis Clin North Am. 5:1991;915-927.
34. Bogard WC Jr, Siegel SA, Leone AO, Damiano E, Shealy DJ, Ely TM, Frederick B, Mascelli MA, Siegel RC, Machielse B, et al. Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide. J Immunol. 150:1993;4438-4449.
35. Shenep JL, Flynn PM, Barrett FF, Stidham GL, Westenkirchner DF. Serial quantitation of endotoxemia and bacteremia during therapy for Gram-negative bacterial sepsis. J Infect Dis. 157:1988;565-568.
36. Van Deventer SJH, Buller HR, Ten Cate JW, Sturk A, Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet. 1:1988;605-608.
37. Rietschel ET, Seydel U, Zahringer U, Schade UF, Brade L, Loppnow H, Feist W, Wang M-H, Ulmer AJ, Flad H-D, et al. Bacterial endotoxin: molecular relationships between structure and activity. Infect Dis Clin North Am. 5:1991;753-779.
38. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanake H, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332:1988;83-85.
39. Vink A, Coulie P, Warnier G, Renauld JC, Stevens M, Donckers D, Van Snick J. Mouse plasmacytomas growth in vivo: enhancement by interleukin-6 and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med. 172:1990;997-1000.
40. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B. Pharmacokinetics of anti-IL-6 therapy in human multiple myeloma: evidence for accumulation of immune complexes and measurements of in vivo cytokine production. Eur J Immunol. 22:1992;2819-2824.
41. Bataille R, Barlogie B, Lu ZY, Rossi J-F, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. of special interest Blood. 86:1995;685-691 A clinical trial of an antiligand strategy for blocking receptor - ligand interaction. An insightful critique of this method.
42. Shields RL, Whether WR, Zioncheck K, O'Connell L, Fendly B, Presta LG, Thomas D, Saban R, Jardieu P. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Appl Immunol. 107:1995;308-312.
43. Presta L, Shields R, O'Connell L, Lahr S, Porter J, Gorman C, Jardieu P. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem. 269:1994;26368-26373.
44. Presta L, Lahr S, Shields R, Porter J, Gorman C, Fendley B, Jardieu P. Humanization of an Ab directed against IgE. J Immunol. 151:1993;2623-2632.
45. Fei DTW, Lowe J, Jardieu P. A novel bioactivity assay for monoclonal antibodies directed against IgE. J Immunol Methods. 171:1994;189-199.
46. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature. 337:1989;525-531.
47. Berkower I, Mostowski H, Bull TE, Murphy D. CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1. of special interest J Infect Dis. 173:1996;863-869 The mechanism of viral inactivation by receptor - Ig.
48. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR, et al. Molecular and biological characterization of a murine ligand for CD40. Nature. 357:1992;80-82.
49. Jin H, Yang R, Marsters SA, Bunting SA, Wurm FM, Chamow SM, Ashkenazi A. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. J Infect Dis. 170:1994;1323-1326.
50. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF receptor study group. of special interest N Engl J Med. 334:1996;1697-1702 An attempt to prevent shock with TNF receptor - Fc, targeting TNF as a ligand. An alternative strategy is to target the TNF receptor with a modified TNF - Fc that is nonstimulatory or even a TNF antagonist.